CG
MTNB icon

Clarus Group’s Matinas BioPharma MTNB Stock Holding History

Clarus Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-240
Closed -$1.9K – 120
2024
Q2 		$1.9K Hold
240
– – ﹤0.01% 115
2024
Q1 		$3.25K Hold
240
– – ﹤0.01% 107
2023
Q4 		$2.59K Hold
240
– – ﹤0.01% 102
2023
Q3 		$1.56K Hold
240
– – ﹤0.01% 110
2023
Q2 		$4.32K Hold
240
– – ﹤0.01% 113
2023
Q1 		$5.64K Hold
240
– – 0.01% 95
2022
Q4 		$6K Hold
240
– – 0.01% 92
2022
Q3 		$8K Hold
240
– – 0.01% 92
2022
Q2 		$9K Hold
240
– – 0.01% 103
2022
Q1 		$10K Hold
240
– – 0.01% 115
2021
Q4 		$13K Hold
240
– – 0.01% 108
2021
Q3 		$16K Hold
240
– – 0.01% 109
2021
Q2 		$9K Hold
240
– – 0.01% 110
2021
Q1 		$12K Hold
240
– – 0.01% 103
2020
Q4 		$17K Buy
+240
New +$11.1K 0.01% 99

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Clarus Group's MTNB Position: Q3 2024 in Review

Clarus Group sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 240 shares — an estimated $1.9K sold.

Clarus Group first reported a position in MTNB in Q4 2020 and held it in 15 quarters. The position peaked at $17K in Q4 2020. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

  • Clarus Group reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
  • Clarus Group sold 240 Matinas BioPharma shares in Q3 2024, an estimated $1.9K.
  • Clarus Group first reported a position in Matinas BioPharma in Q4 2020 and held it in 15 quarters.
  • Clarus Group's Matinas BioPharma position peaked at $17K in Q4 2020.
  • 18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Clarus Group's 13F filing for Q3 2024, filed 21 Oct 2024.